Alnylam Pharmaceuticals (ALNY) Total Non-Current Liabilities (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has 17 years of Total Non-Current Liabilities data on file, last reported at $4.2 billion in Q2 2026.

• Quarterly Total Non-Current Liabilities rose 7.36% year-over-year to $4.2 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $4.2 billion (up 7.36% YoY) and the FY2025 annual result came in at $4.2 billion, up 13.12% from the prior year.
• Total Non-Current Liabilities advanced to $4.2 billion in Q2 2026, from $4.0 billion in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $4.2 billion in Q2 2026 to a low of $2.9 billion in Q1 2022.
• A 5-year average of $3.7 billion and a median of $3.7 billion in 2024 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities advanced 29.54% — and 2024, when it declined 1.5%.
• Tracing ALNY's Total Non-Current Liabilities over 5 years: stood at $3.5 billion in 2022, then gained by 7.16% to $3.7 billion in 2023, then fell by 1.5% to $3.7 billion in 2024, then climbed by 13.12% to $4.2 billion in 2025, then climbed by 0.62% to $4.2 billion in 2026.
• The last three Total Non-Current Liabilities figures came in at $4.2 billion (Q2 2026), $4.0 billion (Q1 2026), and $4.2 billion (Q4 2025), per Business Quant data.